Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate

ATAGÜNDÜZ, IŞIK; TOPTAŞ, TAYFUR; Deniz, Rabia; Kara, Osman; Eser, All; Sezgin, Aslihan; Ozgumus, Toluy; Gecgel, Fatma; Tuglularl, Tulin

doi:10.1016/j.clml.2016.09.006

Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate

Copy For Citation

ATAGÜNDÜZ I., TOPTAŞ T., Deniz R., Kara O., Eser A., Sezgin A., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.17, no.2, pp.120-125, 2017 (SCI-Expanded)

Publication Type: Article / Article
Volume: 17 Issue: 2
Publication Date: 2017
Doi Number: 10.1016/j.clml.2016.09.006
Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.120-125
Marmara University Affiliated: Yes

Abstract

The significance of molecular response depth is not well defined in patients with chronic phase chronic myeloid leukemia (CP-CML) under imatinib treatment. We retrospectively evaluated clinical records of 178 patients with CP-CML. Eighty-eight patients achieved complete molecular response during long term follow-up. Our results implicate that deeper molecular response is associated with improvement in disease outcome and a slight prolongation in progression-free survival.